Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00385138 · ClinicalTrials.gov registry record · Phase 3
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
A Phase 3 study, sponsored by The Medicines Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5,364
- Enrollment target
NCT00385138: Clinical Trial Phase 3 study, sponsored by The Medicines Company.
NCT00385138 is a Phase 3 study that was terminated before completion, run by The Medicines Company. The registered enrollment target is 5,364 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (595% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00385138, a Phase 3 study, was terminated before completion, sponsored by The Medicines Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5,364 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a composite of all-cause mortality, myocardial infarction (MI), and ischemia-driven revascularization (IDR).
Primary Outcome
mITT population; (composite incidence)
Interventions
- DRUG clopidogrel
- DRUG Cangrelor
- DRUG Placebo bolus & placebo infusion
- DRUG Placebo capsules - end of PCI
- DRUG Placebo capsules - end of infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,364 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Why NCT00385138 stopped before completion
NCT00385138 is an interventional study that assigns participants to a tested intervention. Its 5,364 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (595% higher).
The record links to 0 conditions, and to 5 interventions - of which clopidogrel is the first listed.
NCT00385138 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00385138 about?
NCT00385138 is a clinical study titled "Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.". The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a composite of all-cause mortality, myocardial infarction (MI), and ischemi...
What is the current status of trial NCT00385138?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5,364 participants. The study started on 2006-09. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00385138?
The interventions under investigation include: clopidogrel (DRUG), Cangrelor (DRUG), Placebo bolus & placebo infusion (DRUG), Placebo capsules - end of PCI (DRUG), Placebo capsules - end of infusion (DRUG).
Who is sponsoring clinical trial NCT00385138?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00385138's enrollment target sits among peer trials
5,364 45th of 2000 higher than 1,956 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05836987 · 5,350 participants · Phase 3
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- NCT05373771 · 5,328 participants · NA
Sickle Cell Improvement: Enhancing Care in the Emergency Department
- NCT05722769 · 5,408 participants · NA
CSTOP Now! Child Sex Trafficking Stops With You
- NCT04295486 · 5,478 participants · Phase 2
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia